NCT04539639View on ClinicalTrials.gov

Clinical Study of Jaktinib in the Treatment of Patients With Moderate and Severe Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

166

Participants

Timeline

Start Date

December 2, 2020

Primary Completion Date

May 19, 2022

Study Completion Date

May 19, 2022

Conditions
Atopic Dermatitis
Interventions
DRUG

Jaktinib

In the morning: 1 tablet of 50mg and 75mg placebo, 1 tablet of 50mg Jaktinib; In the evening: 1 tablet of 50mg and 75mg placebo, 1 tablet of 50mg Jaktinib.

DRUG

Jaktinib

In the morning: 2 tablet of 50mg placebo, 1 tablet of 75mg Jaktinib; In the evening: 2 tablet of 50mg placebo, 1 tablet of 75mg Jaktinib.

DRUG

Jaktinib

In the morning: 1 tablet of 75mg placebo, 2 tablet of 50mg Jaktinib; In the evening: 1 tablet of 75mg placebo, 2 tablet of 50mg Jaktinib.

DRUG

placebo

In the morning: 2 tablet of 50mg placebo, 1 tablet of 75mg placebo;In the evening: 2 tablet of 50mg placebo, 1 tablet of 75mg placebo.

Trial Locations (1)

410011

The second xiangya hospital of central south university, Changsha

All Listed Sponsors
lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY

NCT04539639 - Clinical Study of Jaktinib in the Treatment of Patients With Moderate and Severe Atopic Dermatitis | Biotech Hunter | Biotech Hunter